Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection

Published:2014-04 Issue:6 Volume:59 Page:2083-2091
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Kumada Hiromitsu¹,Suzuki Yoshiyuki¹,Ikeda Kenji¹,Toyota Joji²,Karino Yoshiyasu²,Chayama Kazuaki³,Kawakami Yoshiiku³,Ido Akio⁴,Yamamoto Kazuhide⁵,Takaguchi Koichi⁶,Izumi Namiki⁷,Koike Kazuhiko⁸,Takehara Tetsuo⁹,Kawada Norifumi¹⁰,Sata Michio¹¹,Miyagoshi Hidetaka¹²,Eley Timothy¹³,McPhee Fiona¹³,Damokosh Andrew¹³,Ishikawa Hiroki¹²,Hughes Eric¹³

Affiliation:

1. Toranomon HospitalTokyo Japan

2. Sapporo‐Kosei General HospitalSapporo Japan

3. Hiroshima UniversityHiroshima Japan

4. Kagoshima UniversityKagoshima Japan

5. Okayama UniversityOkayama Japan

6. Kagawa Prefectural Central HospitalKagawa Japan

7. Musashino Red Cross HospitalTokyo Japan

8. University of TokyoTokyo Japan

9. Osaka UniversityOsaka Japan

10. Osaka City UniversityOsaka Japan

11. Kurume UniversityFukuoka Japan

12. Bristol‐Myers KKTokyo Japan

13. Bristol‐Myers Squibb Research & DevelopmentPrinceton NJ USA

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep.27113

Reference21 articles.

1. Boceprevir for Untreated Chronic HCV Genotype 1 Infection

2. Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection

3. JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2014 Update for Genotype 1

4. Telaprevir for Retreatment of HCV Infection

5. Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection

Cited by 500 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Direct‑acting antiviral treatment is safe and effective for chronic HCV patients with psychiatric disorders;Experimental and Therapeutic Medicine;2023-07-07

2. Current elimination status of hepatitis C virus‐infected maintenance hemodialysis patients in Iwate Prefecture, Japan;Therapeutic Apheresis and Dialysis;2023-05

3. The N-sulfonyl carboxamide moiety as a privileged structure in approved drugs;Privileged Scaffolds in Drug Discovery;2023

4. Primary Neoplasms of the Liver;Holland‐Frei Cancer Medicine;2022-10-21

5. Outcomes of Interferon-free Treatment of Hepatitis C Virus Infection Seven Years after Approval and Problems with Drop out during and after Treatment: A Retrospective, Single-center Study;Internal Medicine;2022-10-15

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3